16 September 2022 - Prestige BioPharma said Thursday it has voluntarily withdrawn its EMA application for the re-examination of approving HD201 (Tuznue), a biosimilar referencing Herceptin to treat breast cancer and metastatic gastric cancer.
The withdrawal comes after the company received a negative opinion on the marketing authorisation for HD201 from the EMA's CHMP on May 19.